Greenacres, Florida, USA (October 26, 2020) – OXIO Health, Inc.®
(“OXIO”) announces today that its Portfolio Company, PWeR, Inc.®, has completed final Alpha testing of its’ new telemedicine module. PWeR® is a patented (patent pending), award winning, patient-centered Electronic Health Record (EHR). This new feature has been introduced to live testing and has received excellent reviews. PWeR will be undergoing further enhancement and upgrade during preparation for recertification in 2021.
Noel J. Guillama, President of OXIO commented, “COVID-19 has crystalized the demand for Remote Patient Care. This demand has brought to the forefront the unique strengths of our patient centered EHR platform that now includes real time patient scheduling and on-demand HIPAA-compliant patient Telemed Portal. Further, we expect to bring an entire new suite of remote care connected off-the-shelf devices in 2021 featuring additional patient’s ( patent issued on data integration) vital sign and key health metrics, AI, predictive medicine, and more robust clinical telemetry tools that will automatically update patient information and will dramatically improve the wellness and clinical patient data, allowing providers of care to obtain actionable real time information directly from the patient.”
The Company noted that telemedicine provided a “high-value” to millions of Americans that needed medical care, and an encounter with their physician; but were required to remain sheltered at home during a national lock-down and reduce their exposure to COVID-19. Media reports have noted up to an 8,000% increase in telemedicine use at the peak shutdown of the U.S. economy in April and May, and the use continues to be 4 to 5 times pre-COVID levels. OXIO believes the biggest value to telemedicine, for both provider and patient, is when telemedicine is integrated with the EHR used by the current providers of care to the patient. This avoids fragmentation of data and treatment inconsistency for the patient; particularly if the patients’ normal care provider is not on the telemedicine encounter, as has been the case for millions of Americans. OXIO’s new module does this.
Mr. Guillama added, “We have been witnessing the growth in telemedicine since the 1990s however, nothing prepared us for the COVID-19 pandemic. Going forward, we believe telemedicine will be another permanent resource enhancement for providers; expanding what has been the tried and true traditional “telephone call”. This enhanced means of communication, supported by high-speed internet, will allow the patients primary care provider to use another tool to improve quality service, reduce cost, provide real- time care, and in many cases; avoid higher escalation of the patient condition by delaying intervention in what could be a critical medical episode. This is a Win-Win! Along with our other on-going innovations in our portfolio, including our new care delivery system and 21st century medical office, 2021 will be a historic year for OXIO as patient care, health, and wellness come even closer together and take center stage in an industry merging new delivery systems and technology.”
OXIO Health sponsored the development and deployment of PWeR®, a cutting-edge, patented and patent-pending healthcare technology platform that has been designed to bridge the gaps of communication and exchange patient information throughout the healthcare delivery on a real time basis. PWeR is capable of integrating the functions a physician/provider, clinician and related professionals utilize in one patient-centric, web-based platform. We are positioned to be a catalyst for change as we take aim at the $700 billion inefficiency gap in the United States healthcare industry.
For more information visit www.pwer.com
About OXIO Health®, Inc.
OXIO Health, Inc. is a new, multifaceted healthcare innovations company that realized medical care and medical technology had to be merged in a new, 21st century platform, to bring more value and improve quality; much of which still remains elusive in healthcare today. Healthcare in the U.S today is a US$3.5 trillion industry with expectation to reach over US$6 trillion by 2030, as 10,000 new baby boomers reach retirement age daily through this period. We have assembled the best systems in our Portfolio of Companies driven to be a change agent in this industry that has resisted change for 50 years; however, due to the lessons-learned from the COVID-19 pandemic patients, provider and payors are now receptive of these needed changes in the delivery of care.
For more information visit www.oxiohealth.io
United States of Helathcare Blogs: https://oxiohealth.io/news-3/
Healthcare 2030 Podcast: https://oxiohealth.io/podcasts/
Certain statements contained in this news release, which are not based on historical facts, are forward-looking statements as the term is defined in the Private Securities Litigation Reform Act of 1995 and are subject to substantial uncertainties and that may cause actual results to materially differ from projections. Forward-looking statements can be identified by the use of words such as “expects,” “plans,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates” “could” and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by these forward-looking statements. Such risk factors include, without limitation, the ability of the Company to properly execute its business model, to raise substantial and immediate additional capital to implement its business model, to continue revenue growth trend in fiscal year(s) 2021 and beyond, , to control patient medical cost relative to income received, to attract and retain executive, management and operational personnel, to continue growing its patient base, to negotiate favorable current debt and future capital raises, to negotiate favorable agreements with a diversified provider base and to continue to supply the services needed by HMO clients as well as physician member and clients. We have further risk in the deployment of our technology platform, the utilization by our clients, technical and software setbacks, cost of development, as well as the capital to deploy it. We are subject further to interruptions of service. Company does not undertake any obligation to publicly update any forward-looking statements. As a result, investors should not place undue reliance on these forward-looking statements. On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus (the “COVID-19 Outbreak”). In March 2020, the WHO classified the COVID-19 Outbreak as a pandemic, based on the rapid increase in exposure globally. The full impact of the COVID-19 Outbreak continues to evolve. The impact of the COVID-19 Outbreak on the Company’s activities is unpredictable.